The arachidonic acid-LTB4-BLT2 pathway enhances human B-CLL aggressiveness

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 11, 2014, Pages 2096-2105

  Guriec, Nathalie ^a   Le Jossic Corcos, Catherine ^b   Simon, Brigitte ^b   Ianotto, Jean Christophe ^a   Tempescul, Adrian ^a   Dréano, Yvonne ^b   Salaün, Jean Pierre ^b   Berthou, Christian ^a   Corcos, Laurent ^b  

^a CHU MORVAN   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

Author keywords

B CLL; BLT2; Disease progression; LTB4; PPAR

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BLT2 PROTEIN; CALCIUM INDEPENDENT PHOSPHOLIPASE A2; CD5 ANTIGEN; CYTOCHROME P450; CYTOCHROME P450 4F3A; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4; MEMBRANE RECEPTOR; POLYUNSATURATED FATTY ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD LEVEL; CELL PROLIFERATION ASSAY; CHRONIC LYMPHATIC LEUKEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING;

EID: 84908065951     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.07.016     Document Type: Article

References (50)

1. Boelens J., Lust S., Vanhoecke B., Offner F. Chronic lymphocytic leukemia. Anticancer Res. 2009, 29:605-616.
2. Masood A., Shahshahan M.A., Jazirehi A.R. Novel approaches to modulate apoptosis resistance: basic and clinical implications in the treatment of chronic lymphocytic leukemia (CLL). Curr. Drug Delivery 2012, 9:30-40.
3. Gamberale R., Geffner J., Arrosagaray G., Scolnik M., Salamone G., Trevani A., Vermeulen M., Giordano M. Non-malignant leukocytes delay spontaneous B-CLL cell apoptosis. Leukemia 2001, 15:1860-1867.
4. Munk-Pedersen I., Reed J.C. Micro-environmental interactions and survival of CLL B-cells. Leuk. Lymphoma 2004, 45:2365-2372.
5. Audrito V., Vaisitti T., Serra S., Bologna C., Brusa D., Malavasi F., Deaglio S. Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. Cancer Lett. 2013, 328:27-35.
6. Scott K.F., Sajinovic M., Hein J., Nixdorf S., Galettis P., Liauw W., de Souza P., Dong Q., Graham G.G., Russell P.J. Emerging roles for phospholipase A2 enzymes in cancer. Biochimie 2010, 92:601-610.
7. Wang T., Xu J., Yang R., Han Z.C. Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit. Rev. Oncol. Hematol. 2006, 58:1-14.
8. Jakobsson P.J., Larsson P., Feltenmark S., Odlander B., Runarsson G., Björkholm M., Claesson H.E. The 5-lipoxygenase pathway in normal and malignant human B lymphocytes. Adv. Prostaglandin Thromboxane Leukot. Res. 1995, 23:293-298.
9. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2011, 294:1871-1875.
10. Ryan E.P., Pollock S.J., Kaur K., Felgar R.E., Bernstein S.H., Chirazzi N., Phipps R.P. Constitutive and activation-inducible cyclooxygenase-2 enhances survival of chronic lymphocytic leukemia B cells. Clin. Immunol. 2006, 120:76-90.
11. Secchiero P., Barbarotto E., Gonelli A., Tiribelli M., Zerbinati C., Celeghini C., Agostinelli C., Pileri S.A., Zauli G. Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia. Am. J. Pathol. 2005, 167:1599-1607.
12. Tsukada N., Burger J.A., Zvaifler N.J., Kipps R.J. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002, 99:1031-1038.
13. Runarsson G., Liu A., Mahshid Y., Feltenmark S., Pettersson A., Klein E., Bjorkholm M., Claesson H.E. Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells. Blood 2005, 105:1274-1279.
14. Ray D.M., Akbiyik F., Bernstein S.H., Phipps R.P. CD40 engagement prevents peroxisome proliferator-activated receptor gamma agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-kappa B-dependent mechanism. J. Immunol. 2005, 174:4060-4069.
15. Sacerdoti D., Gatta A., McGiff J.C. Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostodont. Lipp. Med. 2003, 72:51-71.
16. Corcos L., Lucas D., Le Jossic-Corcos C., Dréano Y., Simon B., Plée-Gautier E., Amet Y., Salaün J.P. Human cytochrome P450 4F3: structure, functions, and prospects. Drug Metabol. Drug Interact. 2012, 27:63-71.
17. Christmas P., Carleso N., Shang H., Cheng S.M., Weber B.M., Preffer F.I., Scadden D.T., Soberman R.J. Myeloid expression of cytochrome P450 4F3 is determined by a lineage-specific alternative promoter. J. Biol. Chem. 2003, 278:25133-25142.
18. Kikuta Y., Ymashita Y., Kashiwagi S., Tani K., Okada K., Nakata K. Expression and induction of CYP4F subfamily in human leukocytes and HL60 cells. Biochim. Biophys. Acta 2004, 1683:7-15.
19. Chung J.W., Kim G.Y., Mun J.C., Ahn J.Y., Seong C.M., Kim J.H. Leukotriene B4 pathway regulates the fate of the hematopoietic stem cells. Exp. Mol. Med. 2005, 37:45-50.
20. Yamaoka K.A., Claesson H.E., Rosen A. Leukotriene B4 enhances activation, proliferation and differentiation of human B lymphocytes. J. Immunol. 1989, 143:1996-2000.
21. Murakami K., Ide T., Suzuki M., Mochizuki T., Kadowaki T. Evidence for direct binding of fatty acids and ecosanoids to human peroxisome proliferators-activated receptor alpha. Biochem. Biophys. Res. Commun. 1999, 260:609-613.
22. Devchand P.R., Keller H., Peters J.M., Vasquez M., Gonzalez F.J., Wahli W. The PPAR-alpha-leukotriene B4 inflammation pathway to inflammation control. Nature 1996, 384:39-43.
23. Harmon G.S., Lam M.T., Glass C.K. PPARs and lipid ligand in inflammation and metabolism. Chem. Rev. 2011, 111:6321-6340.
24. Padilla J., Kaur K., Harris S.G., Phipps R.P. PPAR-gamma-mediated regulation of normal and malignant B lineage cells. Ann. N. Y. Acad. Sci. 2000, 905:97-109.
25. Wang L.H., Yang X.Y., Zhang X., Huang J., Hou J., Li J., Xiong H., Mihalic K., Zhu H., Xiao W., Farrar W.L. Transcriptional inactivation of STAT3 by PPAR-gamma suppresses IL-6-responsive multiple myeloma cells. Immunity 2004, 20:205-218.
26. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., Glass C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005, 122:707-721.
27. Zanderbergen F., Mandard S., Escher P., Tan N.S., Patsouris D., Jatkoes T., Rojas-Caro S., Madores S., Wahli W., Tafuri S., Müller M., Kersten S. The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem. J. 2005, 392:313-324.
28. Wang C., Pattabiraman N., Zhou J.N., Fu M., Sakamaki T., Albanese C., Li Z., Wu K., Hulit J., Neumeister P., Novikoff P.M., Brownlee M., Scherer P.E., Jones J.G., Whitney K.D., Donehower L.A., Harris E.L., Rohan T., Johns D.C., Pestell R.G. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol. Cell. Biol. 2003, 23:6159-6173.
29. Matutes E., Owusu-Ankomah K., Morilla R., Garcia Marco J., Houlihan A., Que T.H., Catovsky D. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of chronic lymphocytic leukemia. Leukemia 1994, 8:1460-1465.
30. Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F., Thomas M., Tchernia G., Jacquillat C., Boivin P., Lesty C., Duault M.T., Monconduit M., Belabbes S., Gremy F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, 48:198-206.
31. Guriec N., Daniel C., Le Ster K., Hardy E., Berthou C. Cytokine-regulated expression and inhibitory function of FcgammaRIIB1 and -B2 receptors in human dendritic cells. J. Leukoc. Biol. 2006, 79:59-70.
32. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
33. Deberardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
34. Candido J., Hagemann T. Cancer-related inflammation. J. Clin. Immunol. 2013, 33:S79-S84.
35. Greene E.R., Huang S., Serhan C.N., Panigrahy D. Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat. 2011, 96:27-36.
36. Ryan E.P., Bushnell T.P., Friedman A.E., Rahman I., Phipps R.P. Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells. Cancer Immunol. Immunother. 2008, 57:347-358.
37. Bernard M.P., Bancos S., Sime P.J., Phipps R.P. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr. Pharm. Des. 2008, 14:2051-2060.
38. Kara I.O., Sahin B. COX-2 inhibitory treatment in chronic lymphocytic leukemia: a preliminary clinical study. Leuk. Lymphoma 2004, 45:1495-1496.
39. Kim H., Choi J.A., Park G.S., Kim J.H. BLT2 up-regulates interleukin-8 production and promotes the invasiveness of breast cancer cells. PLoS One 2012, 7:e49186.
40. Cho N.K., Joo Y.C., Wei J.D., Park J.I., Kim J.H. BLT2 is a pro-tumorigenic mediator during cancer progression and a therapeutic target for anti-cancer drug development. Am. J. Cancer Res. 2013, 3:347-355.
41. Hewamana S., Alghazal S., Lin T.T., Clement M., Jenkins C., Guzman M.L., Jordan C.T., Neelakantan S., Crooks P.A., Burnett A.K., Pratt G., Fegan C., Rowntree C., Brennan P., Pepper C. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008, 111:4681-4689.
42. Liu Z., Hazan-Halevy I., Harris D.M., Li P., Ferrajoli A., Faderl S., Keating M.J., Estrov Z. STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells. Mol. Cancer Res. 2011, 9:507-515.
43. Thotala D., Craft J.M., Ferraro D.J., Kotipatruni R.P., Bhave S.R., Jaboin J.J., Hallahan D.E. PLoS One 2013, 19:e69688.
44. Patel M.I., Singh J., Niknami M., Kurek C., Yao M., Lu S., Maclean F., King N.J., Gelb M.H., Scott K.F., Russell P.J., Boulas J., Dong Q. Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer. Clin. Cancer Res. 2008, 14:8070-8079.
45. Song Y., Wilkins P., Hu W., Murthy K.S., Chen J., Lee Z., Oyesanya R., Wu J., Barbour S.E., Fang X. Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. Biochem. J. 2007, 406:427-436.
46. Roshak A.K., Capper E.A., Stevenson C., Eichman C., Marshall L.A. Human calcium-independent phospholipase A2 mediates lymphocyte proliferation. J. Biol. Chem. 2000, 275:35692-35698.
47. Nakanishi M., Rosenberg D.W. Role of cPLA2 alpha and arachidonic acid in cancer. Biochem. Biophys. Acta 2006, 1761:1335-1343.
48. Lehrke M., Lazar M.A. The many faces of PPAR-gamma. Cell 2005, 123:993-999.
49. Spaner D.E., Lee E., Shi Y., Wen F., Li Y., Tung S., McCaw L., Wong K., Gary-Gouy H., Dalloul A., Ceddia R., Gorzcynski R. PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia 2013, 27:1090-1099.
50. Tung S., Shi Y., Wong K., Zhu F., Gorczynski R., Laister R.C., Minden M., Blechert A.K., Genzel Y., Reichl U., Spaner D.E. PPAR-alpha and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood 2013, 122:969-980.